Stocks Health care VCRE
NASDAQ · Health careVicore Pharma Holding AB (VCRE)
We have not processed filings for Vicore Pharma Holding AB yet. This page fills in on its own once we have read them.
Key facts about Vicore Pharma Holding AB
- Net worth
- Vicore Pharma Holding AB has a market value (market cap) of $3.2B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
What Vicore Pharma Holding AB does
Vicore Pharma Holding AB is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VCRE.
Earnings: every quarter and the next report date
Latest SEC filings
What Vicore Pharma Holding AB has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 3, 2026
- October 22, 2026
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026
- August 21, 2026
- August 21, 2026
- July 6, 2026
- June 30, 2026Form SEC STAFF ACTION filing SEC STAFF ACTION
- June 9, 2026Form 20FR12B/A filing 20FR12B/A
Questions about VCRE
What does Vicore Pharma Holding AB do?
Vicore Pharma Holding AB is a company in the Health care sector, listed on NASDAQ as VCRE. Its shares trade on NASDAQ under the ticker VCRE.
What is Vicore Pharma Holding AB's net worth?
Vicore Pharma Holding AB has a market value (market cap) of $3.2B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Vicore Pharma Holding AB last report?
Its newest filing of any kind is the foreign issuer update from November 5, 2026.
Similar companies
Compare VCRE with
Follow VCRE
Get an email when Vicore Pharma Holding AB files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vicore Pharma Holding AB tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.